Background risk should be taken into account when reporting vaccine effectiveness
- PMID: 35043536
- DOI: 10.1111/ajt.16961
Background risk should be taken into account when reporting vaccine effectiveness
Comment on
-
Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic.Am J Transplant. 2022 Mar;22(3):801-812. doi: 10.1111/ajt.16902. Epub 2021 Dec 10. Am J Transplant. 2022. PMID: 34860470 Free PMC article.
References
REFERENCES
-
- Reischig T, Kacer M, Vlas T, et al. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. Am J Transplant. 2021. doi:10.1111/ajt.16902
-
- Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63(6):1055-1068.
-
- CMMID COVID-19 Working Group, Davies NG, Jarvis CI, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593(7858):270-274. doi:10.1038/s41586-021-03426-1
-
- Angel Y, Spitzer A, Henig O, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021;325(24):2457. doi:10.1001/jama.2021.7152
-
- Komenda M, Bulhart V, Karolyi M, et al. Complex reporting of the COVID-19 epidemic in the Czech Republic: use of an interactive web-based app in practice. J Med Internet Res. 2020;22(5):e19367. doi:10.2196/19367
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources